Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Immutep ( (IMMP) ) is now available.
Immutep Limited announced significant advancements in its global TACTI-004 Phase III trial aimed at treating advanced/metastatic non-small cell lung cancer using eftilagimod alfa (efti) in combination with KEYTRUDA® and chemotherapy. As of December 16, 2025, the trial has enrolled 289 patients globally and achieved regulatory approval in 27 countries. The company cites robust progress, with over 120 clinical sites activated worldwide, and is on track for key milestones, including a futility analysis in early 2026 and completion of patient enrollment later that year. These developments highlight Immutep’s competitive positioning in immunotherapy and its commitment to advancing transformative treatments.
The most recent analyst rating on (IMMP) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall stock score is primarily impacted by its challenging financial performance, characterized by persistent losses and negative cash flows. However, positive technical indicators provide some optimism, suggesting potential short-term momentum. The valuation remains weak due to negative earnings, typical for a biotech firm in its development phase.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company is a leader in advancing treatments related to Lymphocyte Activation Gene-3 (LAG-3), leveraging this expertise to enhance immune system responses. Immutep’s diversified portfolio includes cutting-edge therapies under development for solid tumors like non-small cell lung cancer, head and neck cancers, and others.
Average Trading Volume: 658,967
Technical Sentiment Signal: Buy
Current Market Cap: $361.6M
See more insights into IMMP stock on TipRanks’ Stock Analysis page.